It's Not the AI,... It's the Way You Use It: Making LLMs work in the Real World

Authors

DOI:

https://doi.org/10.60733/PMGR.2025.04

Keywords:

Large Language Models (LLMs), CAPA Management, Deviation Investigation, Pharmaceutical Quality Systems, AI Governance, Organizational Change

Abstract

Pharmaceutical deviation and corrective and preventive action (CAPA) processes are broken—plagued by rushed closured, “human error” cliché and data silos. Can large language models (LLMs) fix this, or will they just automate bad habits? Based on expert interviews, this article reimagines LLMs not as decision makers but as devil’s advocates—tools that provoke better thinking, expose bias and deepen investigations. The proposed five-step roadmap demands more than tech: strong data governance, human oversight, iterative validation, small-scale pilots and a cultural shift toward learning. The EU’s draft Annex 22 on Artificial Intelligence (AI), released in July 2025 for public consultation, adds timely pressure—demanding traceability and accountability but risking innovation paralysis if applied too rigidly. The takeaway: LLMs could be transformative, but only if quality leaders have the courage to use them as catalysts for change—not as digital box-tickers in the same old broken system.

Author Biography

Raphaela Mayer-Negm

Raphaela Mayer-Negm is Head of Quality Operations, Boehringer Ingelheim RCV GmbH & Co KG, Vienna.

References

J. Rodríguez-Pérez, Handbook of investigation and effective CAPA systems, Third edition. Milwaukee, WI: Quality Press, 2022.

N. Erdmann, R. Blumenthal, I. Baumann, and M. Kaufmann, “AI Maturity Model for GxP Application: A Foundation for AI Validation | Pharmaceutical Engineering,” ISPE. Accessed: Jun. 24, 2025. [Online]. Available: https://ispe.org/pharmaceutical-engineering/march-april-2022/ai-maturity-model-gxp-application-foundation-ai

European Medicines Agency (EMA), Ed., “Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle_240903.” Sep. 09, 2024.

U.S. Food and Drug Administration (U.S. FDA), “Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products.” Jan. 2025. Accessed: Jun. 24, 2025. [Online]. Available: https://www.fda.gov/media/184830/download

L. Oestreich, K. Auchincloss, and E. Hartmann, “Trends In FDA FY 2024 Inspection-Based Warning Letters,” Pharmaceutical Online. Accessed: May 17, 2025. [Online]. Available: https://www.pharmaceuticalonline.com/doc/trends-in-fda-fy-2024-inspection-based-warning-letters-0001

D. Husman, “Deviation Management - Why Have We Not Solved the Problem?,” David Husman Consult. Accessed: May 17, 2025. [Online]. Available: https://www.davidhusmanconsulting.com/post/10-ways-to-engage-with-your-clients

R. D. Snee, “A Systems Approach to Root Cause Analysis and CAPA Investigations,” in ResearchGate, Philadelphia, PA, 6.12 2017. Accessed: May 17, 2025. [Online]. Available: https://www.researchgate.net/publication/321975850_A_Systems_Approach_to_Root_Cause_Analysis_and_CAPA_Investigations

G. Yenduri et al., “GPT (Generative Pre-Trained Transformer)— A Comprehensive Review on Enabling Technologies, Potential Applications, Emerging Challenges, and Future Directions,” IEEE Access, vol. 12, pp. 54608–54649, 2024, doi: 10.1109/ACCESS.2024.3389497.

N. S. Arden, A. C. Fisher, K. Tyner, L. X. Yu, S. L. Lee, and M. Kopcha, “Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future,” International Journal of Pharmaceutics, vol. 602, p. 120554, Jun. 2021, doi: 10.1016/j.ijpharm.2021.120554.

J. Kell, “How pharmaceutical companies are training their workers on AI,” Business Insider. Accessed: May 18, 2025. [Online]. Available: https://www.businessinsider.com/pharmaceutical-companies-embrace-ai-in-drug-discovery-efforts-2025-3

International Society for Pharmaceutical Engineering (ISPE) GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition), GAMP. Accessed: Sep. 09, 2025. [Online]. Available: https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571

European Medicines Agency (EMA), “Guidance on good manufacturing practice and good distribution practice: Questions and answers | European Medicines Agency (EMA).” Accessed: Mar. 23, 2025. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), “Pharmaceutical Quality System Q10.” Apr. 06, 2008. doi: 10.1163/ej.9789004163300.i-1081.897.

U.S. Food and Drug Administration (U.S. FDA), “Facts About the Current Good Manufacturing Practice (CGMP),” FDA, Aug. 2024, Accessed: Dec. 29, 2024. [Online]. Available: https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp

Downloads

Published

2025-09-12